2026 Global: Electronic Drug Delivery Systems Market-Competitive Review (2032) report
Description
The 2026 Global: Electronic Drug Delivery Systems Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Ten major players drive the electronic drug delivery systems market: Medtronic (headquartered in Dublin, Ireland), Insulet (Acton, United States), Ypsomed (Burgdorf, Switzerland), Terumo (Tokyo, Japan), B. Braun Melsungen AG (Melsungen, Germany), Fresenius Kabi (Bad Homburg, Germany), Boston Scientific (Marlborough, United States), Becton, Dickinson and Company (BD) (Franklin Lakes, United States), Novo Nordisk (Bagsværd, Denmark), and Sanofi (Paris, France). These firms lead innovations in insulin pumps, smart injectors, infusion pumps, connected devices, and related software platforms that enable remote monitoring, dose personalization, and enhanced safety in routine pharmacotherapy. Across regions, these entities pursue regulatory approval, interoperability standards, and cloud-enabled data management to support clinicians and patients in chronic disease management. Market trajectories reflect rising demand for automated dosing, user-friendly interfaces, secure connectivity, and integrated care ecosystems that align with personalized medicine and remote patient monitoring initiatives worldwide. Investors increasingly reward scale, regulatory track records, and robust after-sales support networks globally strong.
Beyond geography, these firms collectively advance EDDS modalities, including infusion pumps, smart injectors, and connected devices. Medtronic’s insulin pump portfolio links to continuous glucose monitoring and analytics, enabling automated insulin delivery. Insulet emphasizes a tubeless pod system that integrates wireless data exchange with platforms for dose tracking. Ypsomed’s mylife pumps complement software for patient education and oversight. Terumo supplies hospital and infusion pumps with precise dosing control and interoperable interfaces. B. Braun Melsungen offers scalable infusion systems for perioperative, oncology, and critical care settings, along with safety features and device connectivity. Fresenius Kabi focuses on IV infusion pumps and compatible infusion management software. Boston Scientific contributes drug-delivery components and delivery systems for chronic diseases. BD provides IV administration devices and safety technologies that support safe handling and dosing accuracy. Novo Nordisk continues to expand dose-memory pens and connected dosing records, while Sanofi integrates delivery devices with patient support tools Globally.
Strategic positioning among these companies is shaped by regulatory clearance, safety standards, and data privacy requirements, which influence device interoperability and post-market surveillance. In developed markets, adoption of automated delivery and connected care platforms aligns with diabetes management guidelines and hospital quality initiatives, while emerging markets emphasize affordability and local manufacturing capabilities. Partnerships and acquisitions have driven portfolio breadth, with manufacturers expanding into integrated solutions: cloud-based analytics, telehealth interfaces, and smart alarms. The populations of people requiring EDDS continue to grow due to diabetes prevalence, cancer therapy, and chronic disease management. Companies pursuing scale and global manufacturing excellence can reduce unit costs and improve supply chain resilience, while those investing in user experience design, clinician training, and patient engagement tend to outperform. The ten firms listed here illustrate the breadth of the EDDS landscape and the complexity of delivering safe, effective, and connected therapies across heterogeneous health systems globally today.
Ten major players drive the electronic drug delivery systems market: Medtronic (headquartered in Dublin, Ireland), Insulet (Acton, United States), Ypsomed (Burgdorf, Switzerland), Terumo (Tokyo, Japan), B. Braun Melsungen AG (Melsungen, Germany), Fresenius Kabi (Bad Homburg, Germany), Boston Scientific (Marlborough, United States), Becton, Dickinson and Company (BD) (Franklin Lakes, United States), Novo Nordisk (Bagsværd, Denmark), and Sanofi (Paris, France). These firms lead innovations in insulin pumps, smart injectors, infusion pumps, connected devices, and related software platforms that enable remote monitoring, dose personalization, and enhanced safety in routine pharmacotherapy. Across regions, these entities pursue regulatory approval, interoperability standards, and cloud-enabled data management to support clinicians and patients in chronic disease management. Market trajectories reflect rising demand for automated dosing, user-friendly interfaces, secure connectivity, and integrated care ecosystems that align with personalized medicine and remote patient monitoring initiatives worldwide. Investors increasingly reward scale, regulatory track records, and robust after-sales support networks globally strong.
Beyond geography, these firms collectively advance EDDS modalities, including infusion pumps, smart injectors, and connected devices. Medtronic’s insulin pump portfolio links to continuous glucose monitoring and analytics, enabling automated insulin delivery. Insulet emphasizes a tubeless pod system that integrates wireless data exchange with platforms for dose tracking. Ypsomed’s mylife pumps complement software for patient education and oversight. Terumo supplies hospital and infusion pumps with precise dosing control and interoperable interfaces. B. Braun Melsungen offers scalable infusion systems for perioperative, oncology, and critical care settings, along with safety features and device connectivity. Fresenius Kabi focuses on IV infusion pumps and compatible infusion management software. Boston Scientific contributes drug-delivery components and delivery systems for chronic diseases. BD provides IV administration devices and safety technologies that support safe handling and dosing accuracy. Novo Nordisk continues to expand dose-memory pens and connected dosing records, while Sanofi integrates delivery devices with patient support tools Globally.
Strategic positioning among these companies is shaped by regulatory clearance, safety standards, and data privacy requirements, which influence device interoperability and post-market surveillance. In developed markets, adoption of automated delivery and connected care platforms aligns with diabetes management guidelines and hospital quality initiatives, while emerging markets emphasize affordability and local manufacturing capabilities. Partnerships and acquisitions have driven portfolio breadth, with manufacturers expanding into integrated solutions: cloud-based analytics, telehealth interfaces, and smart alarms. The populations of people requiring EDDS continue to grow due to diabetes prevalence, cancer therapy, and chronic disease management. Companies pursuing scale and global manufacturing excellence can reduce unit costs and improve supply chain resilience, while those investing in user experience design, clinician training, and patient engagement tend to outperform. The ten firms listed here illustrate the breadth of the EDDS landscape and the complexity of delivering safe, effective, and connected therapies across heterogeneous health systems globally today.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
